One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
R.S.Kristeleit1K.N.Moore2
doi : 10.1016/j.annonc.2022.08.003
Volume 33, Issue 10, October 2022, Pages 989-991
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
R.Obermannová1M.Alsina23A.Cervantes45T.Leong6F.Lordick7M.Nilsson89N.C.T.van Grieken10A.Vogel11E.C.Smyth12ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.07.003
Volume 33, Issue 10, October 2022, Pages 992-1004
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
F.Lordick1F.Carneiro234S.Cascinu5T.Fleitas6K.Haustermans7G.Piessen891011A.Vogel12E.C.Smyth13ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.07.004
Volume 33, Issue 10, October 2022, Pages 1005-1020
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J.S.Frenel1J.W.Kim2N.Aryal3R.Asher3D.Berton1L.Vidal4P.Pautier5J.A.Ledermann6R.T.Penson7A.M.Oza8J.Korach9T.Huzarski10S.Pignata11N.Colombo12T.W.Park-Simon13K.Tamura14G.S.Sonke15A.E.Freimund16…E.Pujade-Lauraine17
doi : 10.1016/j.annonc.2022.06.011
Volume 33, Issue 10, October 2022, Pages 1021-1028
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
B.Ricciuti1J.V.Alessi1A.Elkrief2X.Wang3A.Cortellini4Y.Y.Li56V.R.Vaz1H.Gupta5F.Pecci1A.Barrichello1G.Lamberti1T.Nguyen1J.Lindsay7B.Sharma8K.Felt8S.J.Rodig89M.Nishino10L.M.Sholl9…J.Luo1â€
doi : 10.1016/j.annonc.2022.07.005
Volume 33, Issue 10, October 2022, Pages 1029-1040
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
F.Peyraud1234†J.-P.Guégan3†D.Bodet3I.Nafia3L.Fontan3C.Auzanneau5S.Cousin2G.Roubaud2M.Cabart2F.Chomy2F.Le Loarer5N.Chaput67F.-X.Danlos1D.Planchard8C.Even8M.Khettab8L.Tselikas9B.Besse8…A.Italiano124
doi : 10.1016/j.annonc.2022.07.001
Volume 33, Issue 10, October 2022, Pages 1041-1051
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
T.André12S.Lonardi3K.Y.M.Wong4H.-J.Lenz5F.Gelsomino6M.Aglietta78M.A.Morse9E.Van Cutsem10R.McDermott11A.Hill12M.B.Sawyer13A.Hendlisz14B.Neyns15S.Abdullaev16A.Memaj17M.Lei18M.Dixon19S.Kopetz20M.J.Overman20
doi : 10.1016/j.annonc.2022.06.008
Volume 33, Issue 10, October 2022, Pages 1052-1060
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
B.Lian1L.Si1Z.H.Chi1X.N.Sheng1Y.Kong1X.Wang1H.Tian1K.Li2L.L.Mao1X.Bai1B.X.Tang1X.Q.Yan1S.M.Li1L.Zhou1J.Dai1X.W.Tang3F.W.Ran3S.Yao3…C.L.Cui1
doi : 10.1016/j.annonc.2022.07.002
Volume 33, Issue 10, October 2022, Pages 1061-1070
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
S.L.Groenland1†R.A.G.van Eerden2†K.Westerdijk3M.Meertens4S.L.W.Koolen25D.J.A.R.Moes6N.de Vries4H.Rosing4H.Otten7A.J.E.Vulink8I.M.E.Desar3A.L.T.Imholz9H.Gelderblom10N.P.van Erp11J.H.Beijnen412R.H.J.Mathijssen2A.D.R.Huitema41314N.Steeghs1Dutch Pharmacology Oncology Group (DPOG)
doi : 10.1016/j.annonc.2022.06.010
Volume 33, Issue 10, October 2022, Pages 1071-1082
Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi
J.TanizakiK.NakagawaH.Hayashi
doi : 10.1016/j.annonc.2022.06.006
Volume 33, Issue 10, October 2022, Pages 1083-1084
Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer
M.Brunet12A.Crombé23S.Cousin1L.Vanhersecke24F.Le Loarer24A.Bessede5A.Italiano126
doi : 10.1016/j.annonc.2022.06.007
Volume 33, Issue 10, October 2022, Pages 1084-1085
Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine
K.Ding123F.Chen14N.Priedigkeit5D.D.Brown6K.Weiss78R.Watters178K.M.Levine1T.Heim78W.Li7J.Hooda12P.C.Lucas9J.M.Atkinson126S.Oesterreich12A.V.Lee126
doi : 10.1016/j.annonc.2022.06.005
Volume 33, Issue 10, October 2022, Pages 1085-1088
Risk-adapted modulation through deintensification of cancer treatments: an ESMO classification
J.-M.Hannoun-Levi1C.Gutierrez2C.Polgar34V.Strnad5BCWG of the GEC–ESTRO
doi : 10.1016/j.annonc.2022.06.014
Volume 33, Issue 10, October 2022, Page 1088
